Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0.

IF 5.2 2区医学 Q1 RHEUMATOLOGY

Current opinion in rheumatology Pub Date : 2023-12-18 DOI:10.1097/bor.0000000000000994

Rohith Appalaneni, Nikhila Achanta, Chandra Mohan

引用次数: 0

Abstract

Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized cancer treatment by harnessing the immune system's power to target malignancies. CD19, a B-cell surface antigen, a key target for CAR-T cell therapy in hematological malignancies, displayed remarkable clinical responses. Recently, there has been a growing interest in exploring the application of CD19 CAR-T cell therapy beyond oncology. The rationale for investigating CD19 CAR-T cells in Rheumatology stems from their ability to selectively target B cells, which play a central pathogenic role through autoantibody-dependent and independent mechanisms.

查看原文本刊更多论文

风湿病学中的嵌合抗原受体 T 细胞疗法：B 细胞耗竭 2.0。

嵌合抗原受体 T 细胞疗法（CAR-T）通过利用免疫系统的力量来靶向恶性肿瘤，为癌症治疗带来了革命性的变化。CD19是一种B细胞表面抗原，是CAR-T细胞疗法治疗血液恶性肿瘤的关键靶点，已显示出显著的临床反应。最近，人们对探索 CD19 CAR-T 细胞疗法在肿瘤学以外的应用越来越感兴趣。研究 CD19 CAR-T 细胞在风湿病学中的应用的理由源于其选择性靶向 B 细胞的能力，B 细胞通过自身抗体依赖和独立机制发挥着核心致病作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in rheumatology 医学-风湿病学

CiteScore

9.70

自引率

2.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.